Last reviewed · How we verify
Halog (HALCINONIDE)
Halog (Halcinonide) is a corticosteroid medication originally developed by Ranbaxy and currently owned by Sun Pharma Industries Inc. It targets the glucocorticoid receptor to treat various skin conditions, including atopic dermatitis, contact dermatitis, and plaque psoriasis. Halog is a small molecule corticosteroid that has been FDA-approved since 1974 and is now available as a generic medication. It is used to reduce inflammation and itching in the skin. As an off-patent medication, Halog is widely available from multiple generic manufacturers.
At a glance
| Generic name | HALCINONIDE |
|---|---|
| Sponsor | Sun Pharma |
| Drug class | Corticosteroid [EPC] |
| Target | Glucocorticoid receptor |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
| First approval | 1974 |
Approved indications
- Atopic dermatitis
- Contact dermatitis
- Discoid lupus erythematosus
- Eruption of skin
- Granuloma annulare
- Lichen simplex chronicus
- Plaque psoriasis
- Primary cutaneous T-cell lymphoma
- Pruritus ani
- Pruritus of genital organs
- Scalp psoriasis
- Seborrheic dermatitis
Common side effects
- skin atrophy
- miliaria
- striae
- maceration of the skin
- allergic contact dermatitis
- perioral dermatitis
- hypopigmentation
- acneiform eruptions
- hypertrichosis
- folliculitis
- dryness
- irritation
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |